EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

Introduction

Introduction (cont)

PASI-75 and PASI-90 Responses

Treatment Goals: European Consensus

PASI-90 Is Associated With Improved DLQI Outcome

Proportion of Patients Achieving PASI-75 From Baseline to Week 12 (IXE)

Comparison of Ixekizumab With Etanercept or Placebo in Moderate-to-Severe Psoriasis (UNCOVER-2 and UNCOVER-3): Results From Two Phase 3 Randomized Trials

FIXTURE: Results on PASI for Secukinumab 300 mg

DLQI 0/1 Response at Week 12 and Week 52

Secukinumab Efficacy Data Over 2 Years Randomized Extension of ERASURE and FIXTURE

Secukinumab Efficacy Data Over Two Years Randomized Extension of ERASURE and FIXTURE

Secukinumab 300 mg Retreatment Response

Secukinumab vs Ustekinumab in Moderate-to-Severe Psoriasis Plaques CLEAR study Week 16 results

CASE VIGNETTE #1

Evolution Under Secukinumab

Secukinumab Rapidly Improved Plaque Psoriasis

PASI-75 Is Not Enough for Patients...

Evolution Under Secukinumab

Secukinumab, a First-Line Label in Moderate / Severe Psoriasis

Clinical Case

Clinical Case

Clinical Case

Clinical Case

Clinical Case

What the Patient Would Like to Expect From a Therapy

PASI-75 vs PASI-90

Secukinumab Benefit-Risk Ratio

A 43-Year-Old Man With a PASI-36

Other Findings

How do ACR Responses to Secukinumab Compare to the Therapeutic Environment?

Resolution of Dactylitis and Enthesitis in Response to Secukinumab

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)